Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of PBP1502 vs EU-Humira and US-Humira in Healthy Volunteers
NCT05108259Phase 1Active, not recruiting
- Sponsor
- Prestige Biopharma Limited
- Start
- Mar 2022
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of idacio in rheumatoid arthritis (RA) (3 arms), sponsored by Prestige Biopharma Limited. Primary endpoints: Area Under the Concentration-time Curve From Time Zero to Infinity, Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration and 1 more. Started Mar 2022; status: active, not recruiting.
02
Drugs
idacio
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05108259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05108259.